Veracyte CFO Rebecca Chambers sells $157,394 in VCYT shares

Rebecca Chambers, Chief Financial Officer of Veracyte, Inc. (VCYT), sold $157,394 worth of the company's common stock on September 4, 2026, under a pre-set Rule 10b5-1 trading plan. The sale occurred as VCYT shares were trading at $42.53, which was classified as the most overvalued stock according to InvestingPro analysis. Chambers sold a total of 3,652 shares of VCYT at weighted average prices of $42.8059 and $43.714 per share.

She also sold an additional 3,603 shares on September 2, 2026, for $44.88 per share, totaling $161,702, which was to satisfy tax obligations related to vesting restricted stock units. This sale did not represent a personal transaction by Chambers, who still holds 166,025 shares of VCYT directly. VCYT's financial health score stands at 3.68 out of 5 according to InvestingPro metrics.

Despite the reported sales, Veracyte, Inc. recently reported strong second-quarter 2026 earnings, surpassing Wall Street's expectations with adjusted earnings of $0.54 per share and revenue of $150.3 million, exceeding forecasts of $0.43 per share and $144.6 million in revenue. Analysts, including Freedom Capital and Needham, have adjusted their price targets upwards, citing Veracyte's strong financial performance.

However, Canaccord lowered its price target due to a more cautious revenue outlook for the long term.